GL1X · GenesisL1 explorer

MolNFT v1 · #109643 · protein

Crystal structure of DSCAM1 isoform 1.9, N-terminal four ig domains

4X8X · Down syndrome cell adhesion molecule isoform 1.9: “Crystal structure of DSCAM1 isoform 1.9, N-terminal four ig domains”. X-ray diffraction, 3 ligands (NAG, BMA, MAN), 7 pockets (best druggability 0.83). MolNFT v1 #109643 on…

PDB
4X8X
Type
protein
Length
783 residues
Chains
2
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
Down syndrome cell adhesion molecule isoform 1.9
Ligands
NAG, BMA, MAN
Pockets
7 · best druggability 0.83

Structure

x-ray diffraction · 2 distinct chains · 5% helix, 51% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
ADown syndrome cell adhesion molecule isoform 1.9protein3906% helix, 52% strand—
BDown syndrome cell adhesion molecule isoform 1.9protein3935% helix, 51% strand—

Ligands and binding sites

  • NAG · 2-acetamido-2-deoxy-beta-D-glucopyranose · sugar · 8 copies · chains A, B
  • BMA · beta-D-mannopyranose · sugar · 4 copies · chains A
  • MAN · alpha-D-mannopyranose · sugar · 4 copies · chains B, A
  • GOL · Glycerol · additive · chains B

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

7 pockets found on a 1 Å grid, 3 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
18890.830.85110GOL
2610.660.9423empty
32670.660.8334empty
4620.370.7917empty
5810.350.7620empty

Interfaces

1 interface between chains.

  • A–B · 1454 Ų buried · 21 hydrogen bonds · protein-protein

Modifications

Observed in the structure: 8 disulfide, 4 glycan (disulfide, N-glycosylation).

Compared structures

  • 4X8X · Crystal structure of Dscam1 isoform 1.9, N-terminal four Ig domains · the same entry in another collection · chain A against A, TM-score 1.00

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.